Cognition Therapeutics Aligns with FDA on Phase 3 Trial for Zervimesine

Key Facts

Cognition Therapeutics aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study for Zervimesine in dementia with Lewy bodies. GlobeNewswire reported that the agreement covers the design, patient selection, dosage, and endpoints for the upcoming pivotal trial.

CGTX closed at $0.7466 on October 21, 2026, prior to the announcement of this regulatory pathway intended to reduce clinical development risk for its lead candidate. The USAN Council has adopted Zervimesine as the name for the drug formerly known as CT1812, which demonstrated potential in slowing disease progression during Phase 2 trials.